Patient becomes advocate for rare cancer research
University of Iowa Health Care
Iowa City, Iowa
An Iowa cancer patient is helping shape the future of treatment after turning a life-altering diagnosis into a mission to advance research and support other patients. According to Medicine Iowa, the patient was diagnosed with neuroendocrine tumors (NETs) in 2005 after initially experiencing unusual symptoms, including facial flushing and gastrointestinal issues. A specialized test confirmed the presence of the rare cancer, which often grows slowly and can go undetected for years before spreading, making early diagnosis and treatment especially challenging.
After the diagnosis, the patient sought care at University of Iowa Health Care, home to one of the nation’s leading centers for NET treatment and research. There, the patient enrolled in a clinical trial for peptide receptor radionuclide therapy, a targeted treatment designed to bind to and destroy cancer cells while slowing tumor growth. The trial helped establish the therapy’s safety in the United States and highlights the critical role clinical research plays in developing new treatments, particularly for cancers that do not respond well to traditional chemotherapy.
Today, the patient has become a research advocate, using personal experience to raise awareness and contribute to ongoing scientific efforts. Advocates often work alongside researchers and clinicians, offering insight that helps guide study design and improve patient-centered care. At UI Health Care, the neuroendocrine tumor program now serves hundreds of patients each year and maintains a nationwide registry to support research.